Prognostic factors in low-stage nonseminomatous testicular cancer

ONCOLOGY

Volumn 10, Issue 9, 1996, Pages 1359-1374

  Moul, Judd W ^a,b   Heidenreich, Axel ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADULT; CANCER STAGING; GENETIC MARKER; GERM CELL TUMOR; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; ORCHIECTOMY; PATHOLOGY; PROGNOSIS; RETROPERITONEUM; REVIEW; RISK FACTOR; RISK MANAGEMENT; TESTIS TUMOR; YOLK SAC TUMOR;

ADULT; ENDODERMAL SINUS TUMOR; GENETIC MARKERS; GERMINOMA; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; ORCHIECTOMY; PROGNOSIS; RETROPERITONEAL SPACE; RISK FACTORS; RISK MANAGEMENT; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030228890     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Boring CC, Squires TS, Tong T: Cancer statistics, 1993. CA Cancer J Clin 43:7-26, 1993.
2. Moul JW: Pitfalls in the management of testicular cancer patients and complications of therapy, in Rous SN (ed): Urology Annual, vol 6, pp 161-197. New York, Norton Medical Books, 1992.
3. Donohue JP, Thornhill JA, Foster RS, et al: Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer: Review of the Indiana University experience 1965-1989. Br J Urol 71:326-335, 1993.
4. Droz JP, Van Oosterom AT: Treatment options in clinical stage I nonseminomatous germ cell tumors of the testis: A wager on the future? A review. Eur J Cancer 29A:1038-1044, 1993.
5. Peckham MJ, Barrett A, Heroic A, et al: Orchiectomy alone for stage I testicular nonseminoma. Br J Urol 55.754-759, 1983.
6. Vaeth M, Schultz HP, Von der Maase H, et al: Prognostic factors in testicular germ cell tumors. Acta Radiological Oncol 23:271-285, 1984.
7. Fujime M, Chang H, Lin C, et al: Correlation of vascular invasion and metastasis in germ cell tumors of testis: A preliminary report. J Urol 131:1237-1241, 1984.
8. Moriyama N, Daly JJ, Keating MA, et al: Vascular invasion as a prognosticator of metastatic disease in nonseminomatous germ cell tumors of the testis. Cancer 56:2492-2498, 1985.
9. Javadpour N, Young JD, Jr: Prognostic factors in nonseminomatous testicular cancer. J Urol 135:497-499, 1986.
10. Rodriguez PN, Hafez GR, Messing EM: Nonseminomatous germ cell tumor of the testicle: Does extensive staging of the primary tumor predict the likelihood of metastatic disease? J Urol 136:604-608, 1986.
11. Holtl W, Kosak D, Pont, J, et al: Testicular cancer. Prognostic implications of vascular invasion. J Urol 137:683-685, 1987.
12. Sogani PC, Fair WR: Surveillance alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis. Semin Urol 6:53-56, 1988.
13. Hoskin P, Dilly S, Easton D, et al: Prognostic factors in stage I nonseminomatous germ cell testicular tumors managed by orchiectomy and surveillance: Implications for adjuvant chemotherapy. J Clin Oncol 4:1031-1036, 1986.
14. Freedman LS, Jones WG, Peckham MJ, et al: Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchiectomy alone. Lancet 2:294-298, 1987.
15. Dunphy CH, Ayala AG, Swanson DA, et al: Clinical stage I nonseminomatous and mixed germ cell tumors of the testis. Cancer 62:1202-1206, 1988.
16. Fung CY, Kalish LA, Brodsky GL, et al: Stage I nonseminomatous germ cell testicular tumor: Prediction of metastatic potential by primary histopathology. J Clin Oncol 6:1467-1473, 1988.
17. Klepp O, Olsson AM, Henrikson H, et al: Prognostic factors in clinical stage in nonseminomatous germ cell tumors of the testis: Multivariate analysis of a prospective multicenter study. J Clin Oncol 8:509-518, 1990.
18. Jacobson GK, Rorth M, Osterlind K, et al: Histopathological features in stage I nonseminomatous testicular germ cell tumors correlated to relapse. APMIS 98:377-382, 1990.
19. Moul JW, McCarthy WF, Fernandez EB, et al: Percentage of embryonal carcinoma and vascular invasion predict pathologic stage in clinical stage I nonseminomatous testicular cancer. Cancer Res 54:1-3, 1994.
20. Pont J, Holtl W, Kosak D, et al: Risk adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor:a prospective trial. J Clin Oncol 8:16-20, 1990.
21. Levin HS: Prognostic features of primary and metastatic testis germ-cell tumors. Urol Clinics North Am 20(1):39-53, 1993.
22. Sesterhenn IA, Weiss RB, Mostofi FK, et al: Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: A report from the Testicular Cancer Intergroup Study. J Clin Oncol 10:69-78, 1992.
23. Stephenson RA: Surveillance for clinical stage I nonseminomatous testis carcinoma: Rationale and results. Urol Int 46:290-293, 1991.
24. Olivarez D, Ulbright T, DeRiese W, et al: Neovascularization in clinical stage A testicular germ cell tumor: Prediction of metastatic disease. Cancer Res 54:2800-2802, 1994.
25. Friedman NB, Moore RA: Tumors of the testis: Report of 922 cases. Mil Surg 99:573-595, 1946.
26. Dixon FJ, Moore RA: Tumors of the male sex organs, in Atlas of Tumor Pathology, Fascicle 31, vol 32. Washington DC, Armed Forces Institute of Pathology, 1952.
27. Peckham MJ, Barrett A, Husband JE, et al: Orchiectomy alone in testicular stage I nonseminomatous germ cell tumors. Lancet 2:678, 1982.
28. Wishnow KI, Johnson DE, Swanson DA, et al: Identifying patients with low risk clinical stage I nonseminomatous testicular tumors who should be treated by surveillance. Urology 34(6):339, 1989.
29. Allhoff EP, Liedke S, de Riese W, et al: Assessment of individual prognosis for patients with NSGCT/CS I (abstract). J Urol 145:367A, 1991.
30. McLeod DG, Weiss RB, Stablein DM, et al and the Testicular Cancer Intergroup Study: Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol 145:1178-1183, 1991.
31. Moul JW, Foley JP, Hitchcock CL, et a: Flow cytometric and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. J Urol 150:879-883, 1993.
32. Visfeldt J, Giwercman A, Skakkebaek NE: Monoclonal antibody 43-9F: An immunohistochemical marker of embryonal carcinoma of the testis. APMIS 100:63-70, 1992.
33. Albers P, Miller GA, Orazi A, et al:Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical Stage A non-seminomatous testicular germ cell tumors at low risk for occult metastasis. Cancer 75:844-850, 1995.
34. Logothetis CJ, Samuels ML, Trindade A, et al: The prognostic significance of endodermal sinus tumor histology among patients treated for stage III nonseminomatous germ cell tumors of the testis. Cancer 53:122-128, 1984.
35. Pizzocaro G, Zanoni F, Salvioni R, et al: Surveillance or lymph node dissection in clinical stage I non-seminomatous germinal testis cancer. Br J Urol 57:759-162, 1985.
36. Pizzocaro G, Zanoni F, Milani A, et al: Orchiectomy alone in clinical stage I nonseminomatous testis cancer: A critical appraisal. J Clin Oncol 4:35-40, 1986.
37. Pizzocaro G, Zanoni F, Salvioni R, et al: Difficulties of a surveillance study omitting retroperitoneal lymphadenectomy in clinical stage I nonseminomatous germ cell tumors of the testis. J Urol 138:1393-1396, 1987.
38. Raghaven D, Colls B, Levi J, et al: Surveillance for stage I non-seminomatous germ cell tumours of the testis: The optimal protocol has not yet been defined. Br J Urol 61:522-526, 1988.
39. Costello AJ, Mortensen PH, Stillwell RG: Prognostic indicators for failure of surveillance management of stage I nonseminomatous germ cell tumors. Aust NZ J Surg 59:119-122, 1989.
40. Rorth M, Jacobsen GK, Van Der Maase H, et al: Surveillance alone versus radiotherapy after orchiectomy for clinical stage I nonseminomatous testicular cancer. J Clin Oncol 9:1543-1548, 1991.
41. Thompson PI, Nixon J, Harvey VJ: Disease relapse in patients with clinical stage I nonseminomatous germ cell tumor of the testis on active surveillance. J Clin Oncol 6:1597-1603, 1988.
42. Ondrus D, Hornak M, Vrabec J: Low sperm counts as a prognostic factor of progression in stage I nonseminomatous germ cell testicular tumors. Br J Urol 62:82-84, 1988.
43. Horwich A, Nicholls EJ, Hendry WF: Seminal analysis after orchiectomy in stage I teratoma. Br J Urol 62:79-81, 1988.
44. Sledge GW, Eble JN, Roth BJ: Relation of proliferative activity to survival in patients with advanced germ cell cancer. Cancer Res 48:3864, 1988.
45. Allhoff E, Wittekind C, Liedke S, et al: The molecular image analysis computer for assessment of prognosis in testicular tumors. Verh Dtsch Ges Path 74:196, 1990.
46. Fossa SD, Nesland JM, Waehre H, et al: DNA ploidy in the primary tumor from patients with nonseminomatous testicular germ cell tumors clinical stage I. Cancer 67:1874, 1991.
47. Allhoff E, Liedke S, DeRiese W, et al: Assessment of individual prognosis for patients with NSGCT.CSI. J Urol 145:A617, 1991.
48. Bürger RA, Braun MH, Witzsch U, et al: Automated DNA-image analysis in testicular cancer: Value of 5c exceeding rate as prognostic factor. J Urol 149:310-A390, 1993.
49. DeRiese WTW, Walker EB, DeRiese C, et al: Predictive value of proliferative parameters measured by flow cytometry in early stage nonseminomatous germ cell tumors (NSGCT). J Urol 149:453-A962, 1993.
50. Austenfield MS, Bilhartz DL, Nativ O, et al: Flow cytometric DNA ploidy pattern for predicting metastasis of clinical stage I nonseminomatous germ cell testicular tumors. Urology 4(4):379, 1993.
51. DeRiese WT, Albers P, Walker EB, et al: Predictive parameters of biologic behavior of early stage nonseminomatous testicular germ cell tumors. Cancer 74:1335-1341, 1994.
52. Fernandez EB, Sesterhenn IA, McCarthy WF, et al: Proliferating cell nuclear antigen (PCNA) expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. J Urol 152:1133-1138, 1994.
53. Ulbright T, Orazi A, deRiese W, et al: The relationship of p53, PCNA, and S-Phase in non-seminomatous germ cell tumors of the testis (abstract). Lab Invest 68(1):71, 1993.
54. Albers P, Orazi A, Ulbright TM, et al: Prognostic significance of immunohistochemical proliferation markers (KI-67/MIB-1 and proliferation-associated nuclear antigen), p53 protein accumulation, and neovascularization in clinical Stage A nonseminomatous testicular germ cell tumors. Mod Pathol 8:492-497, 1995.
55. McLeod DG, Heidenreich A, Moul JW, et al: Do cell proliferation markers better predict pathological stage in clinical stage I nonseminomas than quantitative histology (abstract)? J Urol 155:547A, 1996.
56. Moul JW, Lance RS, Theune SM, et al: From genes that controls cancer, a new medicine rising. Contemp Urol 4(4):74-87, 1992.
57. Moul JW, Kurnot RA, Bishoff JT, et al: Oncogenes and tumor suppressor genes in urologic oncology, in SN Rous (ed): 1993 Urology Annual, pp 139-170. New York, Norton Medical Books, 1993.
58. Moul JW, Theune SM, Chang EH: Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization. Genes, Chromosomes, and Cancer 5:109-118, 1992.
59. Strohmeyer T, Peter S, Hartmann M, et al: Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. Cancer Res 51:1811-1816, 1991.
60. Cresta CM, Masters JRW, Hickman JA: Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax: Bcl-2 ratio. Cancer Res 56:1834-1841, 1996.
61. Strohmeyer T, Reissman P, Cordon-Cardo C, et al: Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. Proc Natl Acad Sci 88:6662-6666, 1991.
62. Lewis DJ, Sesterhenn IA, McCarthy W, et al: Immunohistochemical expression of p53 tumor suppressor gene protein in adult germ cell testis tumors. J Urol 152:418-423, 1994.
63. DeRiese WTW, Orazi A, Foster RS, et al: The clinical relevance of p53 expression in early stage non-seminomatous germ cell tumor (abstract). J Urol 149(4):311A, 1993.
64. Heidenreich A, Schenkman NS, Sesterhenn IA, et al: Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors. J Urol (submitted), 1996.
65. Chresta CM, Masters JRW, Hickman JA: Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high BAx: Bcl-2 ratio. Cancer Res 56:1834-1841, 1996.